News articles about Exactech (NASDAQ:EXAC) have trended positive on Friday, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Exactech earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 43.2690438458742 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

Shares of Exactech (NASDAQ EXAC) opened at $50.27 on Friday. The firm has a market cap of $722.26, a P/E ratio of 41.78, a P/E/G ratio of 4.07 and a beta of 1.02. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.08 and a quick ratio of 2.09. Exactech has a one year low of $23.30 and a one year high of $50.95.

Exactech (NASDAQ:EXAC) last announced its earnings results on Monday, October 30th. The medical equipment provider reported $0.20 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.03). The company had revenue of $61.40 million during the quarter, compared to analysts’ expectations of $61.78 million. Exactech had a net margin of 0.18% and a return on equity of 7.22%. equities analysts anticipate that Exactech will post 1.29 EPS for the current fiscal year.

A number of equities research analysts have recently issued reports on EXAC shares. Zacks Investment Research downgraded shares of Exactech from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. Gabelli downgraded shares of Exactech from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Robert W. Baird downgraded shares of Exactech from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a research note on Monday, October 23rd. Sidoti downgraded shares of Exactech from a “buy” rating to a “neutral” rating in a research note on Monday, October 23rd. Finally, ValuEngine downgraded shares of Exactech from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. Exactech currently has an average rating of “Hold” and a consensus price target of $49.00.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Insider Buying and Selling by Quarter for Exactech (NASDAQ:EXAC)

Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.